Organoid teams are entering a phase where reviewers ask what the assay can inform, compared with what, and under which uncertainty. The strategic task is to turn model biology into a claim package that survives diligence, funding review, and regulatory-science discussion.

LLMs can speed up evidence work. But if you can’t reproduce and audit what the model changed, your “AI-enabled” pipeline can become a credibility liability.

Qualification of Novel Methodologies ( QoNM ) has moved beyond its old role as a specialist regulatory procedure. It is becoming one of the clearest signals of how Europe intends to judge AI tools, imaging methods, mechanistic models and other next-generation evidence instruments in drug development. For years, the EMA’s Qualification of Novel Methodologies process was easy to leave to specialists. It sat in the part of the regulatory map reserved for biomarkers, technical

A new OECD comparison of the European Union and the United States makes one point impossible to ignore: the next phase of biotechnology leadership will not be won in the lab alone. It will be won in the operating system that moves discoveries into markets. Both jurisdictions have world-class research ecosystems. But they do not convert science into commercial scale in the same way. The United States still leads on the classic translation metrics. It files roughly twice as man